1,2-二氢-2-氧代-4-氯-6-甲基吡啶-3-羧酸乙酯 | 86129-62-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1,2-二氢-2-氧代-4-氯-6-甲基吡啶-3-羧酸乙酯
• 英文名称: ethyl 1,2-dihydro-2-oxo-4-chloro-6-methylpyridine-3-carboxylate
• 英文别名: ethyl 4-chloro-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate；ethyl 4-chloro-6-methyl-2-oxo-1H-pyridine-3-carboxylate
• CAS: 86129-62-6
• 化学式: C₉H₁₀ClNO₃
• 分子量: 215.636
• InChiKey: LCAOURNJLXCNNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2-二氢-2-氧代-4-氯-6-甲基吡啶-3-羧酸乙酯 在 五氯化磷 、 四氯化锡 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 28.0h， 生成 1-chloro-3-methyl-10H-<1>benzothiopyrano<3,2-c>pyridin-10-one
  参考文献：
  名称：

  Aza analogs of lucanthone: synthesis and antitumor and bactericidal properties

  摘要：

  Three types of aza analogues of lucanthone were synthesized for evaluation as antitumor drugs. None of the compounds was found to have significant cytotoxic effects either on Friend tumor cells or on L1210 leukemia cells. However, one of the target compounds, 5,10-dihydro-10-oxo-1-[[3-(diethylamino)propyl]amino]-3-methylpyrido [4,3-b]quinoline, was shown to have noticeable antibiotic properties.

  DOI：

  10.1021/jm00363a022
• 作为产物：
  描述：

  ethyl 2,4-dihydroxy-6-methylnicotinate 在 N,N,N-三乙基-1-丁烷铵氯化物 、 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以44%的产率得到1,2-二氢-2-氧代-4-氯-6-甲基吡啶-3-羧酸乙酯
  参考文献：
  名称：

  FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF

  摘要：

  公开号：

  EP2471789B9

文献信息

• FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
  申请人：FUJII Nobuhiro

  公开号：US20090227561A1

  公开（公告）日：2009-09-10

  The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product. The present invention provides a compound represented by the formula wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR 1 (R 1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s)); R 2 is carbamoyl optionally having substituent(s); and R 3 is hydroxy optionally having substituent(s), or a salt thereof.

  本发明提供了一种具有优异的Smo抑制活性和较低毒性的化合物，该化合物作为药物产品是完全令人满意的。本发明提供了一种由下式表示的化合物： 其中，环A是5-至7-成员环，可选择地具有取代基，其中取代基可选择地与彼此结合形成环；X是O、S或NR1（R1是氢原子或具有取代基的碳氢基团）；R2是氨基甲酰，可选择地具有取代基；R3是羟基，可选择地具有取代基，或其盐。
• Fused heterocyclic derivative and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08217176B2

  公开（公告）日：2012-07-10

  The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product. The present invention provides a compound represented by the formula wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR1 (R1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s)); R2 is carbamoyl optionally having substituent(s); and R3 is hydroxy optionally having substituent(s), or a salt thereof.

  本发明提供了一种化合物，具有优越的Smo抑制活性和较低的毒性，足以作为药物产品。本发明提供的化合物由以下式子表示：其中环A是5-至7-成员环，可选地具有取代基，其中取代基可选择结合在一起形成环；X是O、S或NR1（R1是氢原子或具有取代基的碳氢基团）；R2是氨基甲酰基，可选地具有取代基；R3是羟基，可选地具有取代基，或其盐。
• Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer
  申请人：Ohashi Tomohiro

  公开号：US08486965B2

  公开（公告）日：2013-07-16

  The present invention provides a fused heterocycle derivative having a strong Smo inhibitory activity, and use thereof. Specially, the present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or salt thereof, and a medicament containing the compound or a prodrug thereof, which is an Smo inhibitor or an agent for the prophylaxis or treatment of cancer.

  本发明提供了一种具有强Smoo抑制活性的融合杂环衍生物及其使用。具体而言，本发明涉及一种由式表示的化合物，其中每个符号如规范中定义，或其盐，以及含有该化合物或其前药的药物，其为Smoo抑制剂或癌症预防或治疗剂。
• Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: Modification of the core skeleton for improved solubility
  作者：Tomohiro Ohashi、Yuya Oguro、Toshio Tanaka、Zenyu Shiokawa、Yuta Tanaka、Sachio Shibata、Yoshihiko Sato、Hiroko Yamakawa、Harumi Hattori、Yukiko Yamamoto、Shigeru Kondo、Maki Miyamoto、Mitsuhiro Nishihara、Yoshimasa Ishimura、Hideaki Tojo、Atsuo Baba、Satoshi Sasaki

  DOI：10.1016/j.bmc.2012.07.034

  日期：2012.9

  We recently reported the discovery of the novel pyrrolo[3,2-c] quinoline-4-one derivative 1 as a potent inhibitor of Hedgehog (Hh) pathway signaling. However, the PK evaluation of 1 at high dosage (100 mg/kg) revealed the C-max value 3.63 mu g/mL, likely due to poor solubility of this compound. Efforts to improve solubility by reducing the aromatic ring count of the core system led to N-methylpyrrolo[3,2-c]pyridine derivative 11. Further optimization of the 3-alkoxy group led to compound 11d with acceptable solubility and potent Hh inhibitory activity. Compound 11d suppressed transcription factor Gli1 mRNA expression in tumor-associated stromal tissue and inhibited tumor growth (treatment/control ratio, 3%) in a mouse medulloblastoma allograft model owing to the improved PK profile based on increased solubility. Compound 11d (TAK-441) is currently in clinical trials for the treatment of advanced solid tumors. (C) 2012 Elsevier Ltd. All rights reserved.
• US8217176B2
  申请人：——

  公开号：US8217176B2

  公开（公告）日：2012-07-10